newsfilter
← Latest News
GlobeNewswire·

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for